Related Experiment Video
Updated: Jun 23, 2026
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Specifically targeted gene therapy for small-cell lung cancer
Camilla L Christensen1, Roza Zandi, Torben Gjetting
1Department of Radiation Biology, The Finsen Center, section 6321, Copenhagen University Hospital, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Expert Review of Anticancer Therapy
|April 21, 2009
Summary
Gene therapy offers a promising new avenue for treating small-cell lung cancer (SCLC). This approach involves introducing DNA into cancer cells to induce cell death, addressing the need for advanced SCLC therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Small-cell lung cancer (SCLC) presents a significant clinical challenge due to its high malignancy and poor patient prognosis.
- Current treatment options for SCLC are limited, necessitating the development of novel therapeutic strategies.
- Gene therapy is emerging as a potential treatment modality for various cancers, including SCLC.
Purpose of the Study:
- To review and discuss the current applications of gene therapy in the context of small-cell lung cancer.
- To highlight the challenges and potential of gene therapy for SCLC treatment.
- To explore the necessity of targeted delivery systems for systemic gene therapy in SCLC.
Main Methods:
- Literature review of existing studies on gene therapy for SCLC.
- Analysis of gene therapy principles and their application to SCLC.
- Discussion of systemic administration challenges and delivery vehicle requirements.
Main Results:
- Gene therapy holds promise as a supplementary or alternative treatment for SCLC.
- Effective systemic delivery and tumor targeting are critical for successful gene therapy in disseminated SCLC.
- Various gene therapy strategies are under investigation for SCLC.
Conclusions:
- Gene therapy represents a promising frontier in the management of small-cell lung cancer.
- Further research into targeted delivery systems is essential for advancing gene therapy for SCLC.
- The development of novel gene therapeutic agents could significantly improve outcomes for SCLC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...